Higher parathyroid hormone (PTH) concentrations with the Architect PTH assay than with the Elecsys assay in hemodialysis patients, and a simple way to standardize these two methods

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 3, 2009, Pages 362-366

  Monge, Marie ^a   Jean, Guillaume ^b   Bacri, Jean Louis ^c   Lemaitre, Vincent ^c   Masy, Eric ^c   Joly, Dominique ^d   Souberbielle, Jean Claude ^d,e  

^a LABORATOIRE CERBA   (France)

^b Centre de Rein Artificiel de Tassin   (France)

^c CENTRE HOSPITALIER DE VALENCIENNES   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e INSERM   (France)

Author keywords

Assay standardization; Hemodialysis; Immunoassay; Kidney Disease Outcomes Quality Initiative (K DOQI); Parathyroid hormone

Indexed keywords

PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HEMODIALYSIS PATIENT; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; IMMUNOASSAY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PARATHYROID HORMONE; REAGENT KITS, DIAGNOSTIC; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 63849138682     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.068     Document Type: Article

References (13)

1. National Kidney Foundation. K/DOKI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42(Suppl 3):S1-201.
2. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, et al. The spectrum of bone disease in endstage renal failure - an evolving disorder. Kidney Int 1993;43:436-42.
3. Nussbaum S, Zahradnik R, Lavigne J, Brennan G, Nozawa-Ung K, Kim L, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in press - uncorrected proof in evaluating patients with hypercalcemia. Clin Chem 1987;33:1364-7.
4. Souberbielle JC, Friedlander G, Cormier C. Practical considerations in PTH testing. Clin Chim Acta 2006;366:81-9.
5. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006;70:345-50.
6. Cantor T, Yang Z, Caraini N, Ilamathi E. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem 2006;52:1771-6.
7. Torres PU. The need for reliable serum parathyroid hormone measurements. Kidney Int 2006;70:240-3.
8. Joly D, Drueke T, Alberti C, Houillier P, Lawson-Body E, Martin K, et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis 2008;51:987-95.
9. Reichel H, Esser A, Roth HJ, Schmidt-Gayk H. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 2003;18: 759-68.
10. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, et al. A non (1-84) circulating parathyroid hormone fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998;44:805-9.
11. D'Amour P, Brossard JH, Rousseau L, Nguyen-Yamamoto L, Nassif E, Lazure C, et al. Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int 2005;68:998-1007.
12. Brossard JH, Lepage R, Cardinal H, Roy L, Rousseau L, Dorais C, et al. Influence of glomerular filtration rate on non (1-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 2000;46:697-703.
13. Gao P, Scheibel S, D'Amour P, John M, Rao S, Schmidt-Gayk H, et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implication for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001;16:605-14.